180 related articles for article (PubMed ID: 37759449)
21. miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma.
Yang Y; Li F; Saha MN; Abdi J; Qiu L; Chang H
Clin Cancer Res; 2015 May; 21(10):2399-411. PubMed ID: 25724519
[TBL] [Abstract][Full Text] [Related]
22.
Bolzoni M; Ronchetti D; Storti P; Donofrio G; Marchica V; Costa F; Agnelli L; Toscani D; Vescovini R; Todoerti K; Bonomini S; Sammarelli G; Vecchi A; Guasco D; Accardi F; Palma BD; Gamberi B; Ferrari C; Neri A; Aversa F; Giuliani N
Haematologica; 2017 Apr; 102(4):773-784. PubMed ID: 28057743
[TBL] [Abstract][Full Text] [Related]
23. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
Front Immunol; 2021; 12():792609. PubMed ID: 34880879
[TBL] [Abstract][Full Text] [Related]
24. 4-Methyl-2,4-bis(4-hydroxyphenyl)pent-1-ene (MBP) Targets Estrogen Receptor β, to Evoke the Resistance of Human Breast Cancer MCF-7 Cells to G-1, an Agonist for G Protein-Coupled Estrogen Receptor 1.
Hirao-Suzuki M; Nagase K; Suemori T; Tsutsumi K; Shigemori E; Tanaka M; Takiguchi M; Sugihara N; Yoshihara S; Takeda S
Biol Pharm Bull; 2021; 44(10):1524-1529. PubMed ID: 34602561
[TBL] [Abstract][Full Text] [Related]
25. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma.
Hu Y; Liu H; Fang C; Li C; Xhyliu F; Dysert H; Bodo J; Habermehl G; Russell BE; Li W; Chappell M; Jiang X; Ondrejka SL; Hsi ED; Maciejewski JP; Yi Q; Anderson KC; Munshi NC; Ao G; Valent JN; Lin J; Zhao J
Cancer Res; 2020 May; 80(10):2031-2044. PubMed ID: 32193289
[TBL] [Abstract][Full Text] [Related]
26. The yin-yang effects of immunity: From monoclonal gammopathy of undetermined significance to multiple myeloma.
Yi Z; Ma T; Liu J; Tie W; Li Y; Bai J; Li L; Zhang L
Front Immunol; 2022; 13():925266. PubMed ID: 35958625
[TBL] [Abstract][Full Text] [Related]
27. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.
Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A
J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841
[TBL] [Abstract][Full Text] [Related]
28. The neuroprotective effects of novel estrogen receptor GPER1 in mouse retinal ganglion cell degeneration.
Jiang M; Ma X; Zhao Q; Li Y; Xing Y; Deng Q; Shen Y
Exp Eye Res; 2019 Dec; 189():107826. PubMed ID: 31586450
[TBL] [Abstract][Full Text] [Related]
29. Laboratory testing for monoclonal gammopathies: Focus on monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Willrich MAV; Murray DL; Kyle RA
Clin Biochem; 2018 Jan; 51():38-47. PubMed ID: 28479151
[TBL] [Abstract][Full Text] [Related]
30. Aberrant Levels of miRNAs in Bone Marrow Microenvironment and Peripheral Blood of Myeloma Patients and Disease Progression.
Wang W; Corrigan-Cummins M; Barber EA; Saleh LM; Zingone A; Ghafoor A; Costello R; Zhang Y; Kurlander RJ; Korde N; Roccaro AM; Ghobrial IM; Landgren O; Calvo KR
J Mol Diagn; 2015 Nov; 17(6):669-78. PubMed ID: 26433312
[TBL] [Abstract][Full Text] [Related]
31. Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.
Zavidij O; Haradhvala NJ; Mouhieddine TH; Sklavenitis-Pistofidis R; Cai S; Reidy M; Rahmat M; Flaifel A; Ferland B; Su NK; Agius MP; Park J; Manier S; Bustoros M; Huynh D; Capelletti M; Berrios B; Liu CJ; He MX; Braggio E; Fonseca R; Maruvka YE; Guerriero JL; Goldman M; Van Allen EM; McCarroll SA; Azzi J; Getz G; Ghobrial IM
Nat Cancer; 2020 May; 1(5):493-506. PubMed ID: 33409501
[TBL] [Abstract][Full Text] [Related]
32. Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias.
Testa S; Kumar J; Goodell AJ; Zehnder JL; Alexander KM; Sidana S; Arai S; Witteles RM; Liedtke M
Semin Oncol; 2022 Dec; 49(6):465-475. PubMed ID: 36503855
[TBL] [Abstract][Full Text] [Related]
33. PD-L1/PD-1 Pattern of Expression Within the Bone Marrow Immune Microenvironment in Smoldering Myeloma and Active Multiple Myeloma Patients.
Costa F; Vescovini R; Marchica V; Storti P; Notarfranchi L; Dalla Palma B; Toscani D; Burroughs-Garcia J; Catarozzo MT; Sammarelli G; Giuliani N
Front Immunol; 2020; 11():613007. PubMed ID: 33488620
[TBL] [Abstract][Full Text] [Related]
34. Identification of circulating microRNAs as diagnostic biomarkers for use in multiple myeloma.
Jones CI; Zabolotskaya MV; King AJ; Stewart HJ; Horne GA; Chevassut TJ; Newbury SF
Br J Cancer; 2012 Dec; 107(12):1987-96. PubMed ID: 23169280
[TBL] [Abstract][Full Text] [Related]
35. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
[TBL] [Abstract][Full Text] [Related]
36. Cytogenetic profiles in multiple myeloma and monoclonal gammopathy of undetermined significance: a study in highly purified aberrant plasma cells.
Schmidt-Hieber M; Gutiérrez ML; Pérez-Andrés M; Paiva B; Rasillo A; Tabernero MD; Sayagués JM; Lopez A; Bárcena P; Sanchez ML; Gutiérrez NC; San Miguel JF; Orfao A
Haematologica; 2013 Feb; 98(2):279-87. PubMed ID: 22929983
[TBL] [Abstract][Full Text] [Related]
37. Genistein inhibits the proliferation of human multiple myeloma cells through suppression of nuclear factor-κB and upregulation of microRNA-29b.
Xie J; Wang J; Zhu B
Mol Med Rep; 2016 Feb; 13(2):1627-32. PubMed ID: 26718793
[TBL] [Abstract][Full Text] [Related]
38. MicroRNA and multiple myeloma: from laboratory findings to translational therapeutic approaches.
Rossi M; Amodio N; Di Martino MT; Tagliaferri P; Tassone P; Cho WC
Curr Pharm Biotechnol; 2014; 15(5):459-67. PubMed ID: 24846067
[TBL] [Abstract][Full Text] [Related]
39. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
[TBL] [Abstract][Full Text] [Related]
40.
Wu H; Liu C; Yang Q; Xin C; Du J; Sun F; Zhou L
Autophagy; 2020 Apr; 16(4):683-697. PubMed ID: 31242129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]